Kendric Cromer, 12, is among the first patients to be treated with gene therapy just approved by the F.D.A. that many other ...

Developed in collaboration with Vertex Pharmaceuticals, this therapy treats sickle cell ... editing the faulty gene in a lab, ...

In the meantime current gene therapies remain expensive and challenging to scale up because each patient’s batch of cells has ...

Sickle cell disease causes severe pain that’s hard to treat, but researchers are finding new ways to offer relief ...

Stocks in this week’s article are HCA Healthcare HCA, Hubbell HUBB, Ferrari RACE and Vertex VERX. 4 GARP Stocks to ...

Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. HCA, HUBB, RACE and VERX are some stocks that hold promise.

GC Therapeutics claims it can create off-the-shelf therapies from induced pluripotent stem cells faster and simpler than current methods.

Researchers at multiple AViDD centers confirm that the NIH has offered a 1-year, no-cost extension, but it doesn’t come with ...

“With the full weight of the vacuum sitting over the power brush, you can more easily push it down into the carpet pile to ...

Peter Koo – Assistant Professor at Cold Spring Harbor Laboratory. There are at least millions of mutations ... with approved products like CRISPR Therapeutics and its partner Vertex. With a new ...

GPU-accelerated simulations of Voronoi and vertex models of cells. Initial version published in Computer Physics Communications: https://doi.org/10.1016/j.cpc.2017.06.001 ...

HOUSTON (AP) — Vertex Energy Inc. VTNR) on Thursday reported a loss of $53.8 million in its second quarter. The Houston-based company said it had a loss of 58 cents per share. HOUSTON ...